Sage Therapeutics
215 First Street
Cambridge
MA
02142
United States
Tel: 617-299-8380
Website: https://www.sagerx.com/
About Sage Therapeutics
Sage is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. We are pursuing new pathways with the goal of improving brain health, and our depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Our mission is to make medicines that matter so people can get better, sooner.
Stock Symbol:
SAGE
372 articles about Sage Therapeutics
-
SAGE Therapeutics Announces Collaboration With Washington University To Develop Novel GABA Receptor Small Molecules
12/20/2013
-
SAGE Therapeutics Presents New Data Identifying Highly Selective, Oral Compounds And Novel Approach For The Treatment Of Chronic Epilepsies
12/9/2013
-
SAGE Therapeutics’s Novel Approach To Treatment Of CNS Disorders To Be Highlighted At Leading Industry And Scientific Conferences
11/18/2013
-
SAGE Therapeutics’s Novel Approach To Treatment Of CNS Disorders To Be Highlighted At Leading Industry And Scientific Conferences
11/18/2013
-
SAGE Therapeutics Presents New Mechanistic Insights On Novel Approach To NMDA Receptor Modulation
11/13/2013
-
SAGE Therapeutics’s Discovery of Novel Allosteric Therapeutic Approach for a Broad Range of CNS Disorders Published in Journal of Neuroscience
10/30/2013
-
SAGE Therapeutics Secures $20 Million Series B Financing
10/16/2013
-
Dr. Jeffrey Jonas Leads SAGE Therapeutics as New CEO
8/14/2013
-
SAGE Therapeutics Awarded Collaborative National Institutes of Health (NIH) Grant to Accelerate Development of New Treatment for Fragile X Syndrome
7/31/2013
-
SAGE Therapeutics' Refractory Status Epilepticus Program Demonstrates Efficacy in First-in-Man Experience; Case Study to be Highlighted at International SE Meeting
4/4/2013
-
SAGE Therapeutics Appoints Chief Scientific Officer, Strengthens Management Team
11/30/2011
-
Third Rock Ventures Launches SAGE Therapeutics with $35 Million Backing
10/18/2011